An ACR Convergence 2020 session described both the promises and problems of B-cell therapy.
Plenary Session I focused on growing links between SARS-CoV-2 infection and autoimmune events that are more often seen in rheumatologic diseases.
A retrospective analysis of knee and hip replacements in patients with atrial fibrillation on anticoagulation therapy was one of the presentations during the Plenary II session during ACR Convergence 2020.
Results from the BLISS-LN trial was one of the highlights from the Plenary III session.
The ACR Convergence 2020 Late-Breaking Abstracts session featured six presentations on cutting-edge science.
A new ACR guideline for the management of rheumatoid arthritis (RA) has been drafted and is expected to be approved later this year and published by early spring 2021.
Members of the Global Rheumatology Alliance (GRA) COVID-19 Steering Committee presented data from the COVID-19 GRA Registry on the impact of the pandemic on the rheumatology community.
David Karp, MD, PhD, became the 84th ACR President. Additionally, Kenneth G. Saag, MD, MSc, became ACR President-Elect, and Deborah Dyett Desir, MD, was confirmed by the membership as the new ACR Secretary.
Before delivering his address during ACR Convergence 2020, Anthony S. Fauci, MD, was awarded the ACR Distinguished Global Public Health Award during the special session COVID-19: Public Health and Scientific Challenges.
With Phase 2 of the Accelerating Medicines Partnership (AMP) study of systemic lupus erythematosus (SLE) underway, an ACR Convergence 2020 session featured a panel that reviewed the methods being used […]